NewsFDASaturday, January 10, 2026 · January 10, 2026
First Biosimilar for Gaucher Disease Enzyme Therapy Approved
WHY IT MATTERS
Biosimilar competition may improve access to treatments costing $300K+ annually.
The first biosimilar to imiglucerase for Gaucher disease received FDA approval.
Related conditions
Related news
FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…